Register for our free email digests:
Latest From Dermira Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Commercial Capsules: Autoimmune Positioning; Sanofi In China; Migraine Race; BMS Deal; Clinical Advances
AbbVie outlines how it will stay top dog in autoimmune therapy; Dermira licenses lebrikizumab, threatening pressure on Sanofi/Regeneron's Dupixent; Sanofi has driven up vaccine sales in China after responding to new government distribution rules; Lilly plans a migraine filing; FibroGen, Myokardia and Hansa Medical advance in the clinic and Bristol-Myers shells out up to $2.3bn to turn cold tumors hot. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
- Large Molecule
- Topical Delivery
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Skintelligence Inc.
- North America
- Parent & Subsidiaries
- Dermira Inc.
- Senior Management
Thomas G Wiggans, CEO
Andrew Guggenhime , COO & CFO
Eugene A Bauer, MD, CMO
Chris Griffith, VP, Corp. Dev. & Strategy
Christine Conroy , SVP, Reg. Affairs
Hans Hofland, PhD, VP, Research & Nonclinical Dev.
Lori Lyons-Williams, Chief Commercial Officer
- Contact Info
Phone: (650) 421-7200
275 Middlefield Rd.
Menlo Park, CA 94025
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.